Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.

Veena Hoffman Nina Sahlertz Kristiansen Marie Linder Andrea V Margulis Brandon T Suehs Alejandro Arana Kelesitse Phiri Cheryl Enger Libby Horter Ingvild Odsbu Morten Olesen Susanna Perez-GutthannYihua XuNina Sahlertz KristiansenKwame AppentengStefan de Vogel John D Seegernull null

Published in: Drug safety (2021)

This large, multinational study found no higher risk of MACE, AMI, stroke, CV mortality or all-cause mortality among users of mirabegron relative to users of antimuscarinics.

Keyphrases

atrial fibrillation
type diabetes
risk factors
heart failure
coronary artery disease
acute coronary syndrome
percutaneous coronary intervention